FIELD: chemistry.
SUBSTANCE: invention relates to compounds of formula II and formula VII, and pharmaceutically acceptable salts thereof. In formula II: Y is -O-; R2 is -NO2; R4a is selected from a group consisting of unsubstituted C1-6 alkyl and (heterocyclo)alkyl. In formula VII: Y is selected from a group consisting of -CH2- and -O-; X1, X2, and X3 each independently represents -CR8=; R2 is -NO2; R4a is selected from the group consisting of unsubstituted C1-6 alkyl and (heterocyclo)alkyl; and R8 is hydrogen. (Heterocyclo)alkyl is C1-4 alkyl substituted with one heterocyclyl group, where the heterocyclyl group is 6-member cyclic group containing one ring and one or two oxygen atoms.
EFFECT: disclosed compounds inhibit Bcl-2 proteins and are used in treating a disease, disorder or condition susceptible to Bcl-2 protein inhibition, such as cancer.
4 cl, 4 dwg, 7 tbl, 20 ex
Title | Year | Author | Number |
---|---|---|---|
N-(PHENYLSULFONYL)BENZAMIDES AND RELATED COMPOUNDS AS BCL-2 INHIBITORS | 2017 |
|
RU2722560C1 |
N- (PHENYLSULPHONYL) BENZAMIDES AND RELATED COMPOUNDS AS BCL-2 INHIBITORS | 2017 |
|
RU2744358C2 |
BENZAMIDE COMPOUNDS | 2019 |
|
RU2801647C2 |
APOPTOSIS-INDUCING AGENTS FOR TREATING MALIGNANT TUMOURS AND IMMUNE AND AUTOIMMUNE DISEASES | 2010 |
|
RU2573832C2 |
APOPTOSIS INDUCING AGENTS FOR TREATING MALIGNANT NEW GROWTH, AND IMMUNE AND AUTOIMMUNE DISEASES | 2010 |
|
RU2535347C2 |
APOPTOSIS-INDUCING MEANS FOR TREATMENT OF MALIGNANT TUMOUR AND IMMUNE AND AUTOIMMUNE DISEASES | 2015 |
|
RU2628885C2 |
APOPTOSIS-INDUCING AGENTS FOR TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | 2014 |
|
RU2662812C2 |
APOPTOSIS-INDUCING MEDICATIONS FOR TREATING CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | 2010 |
|
RU2554346C2 |
SOLID DISPERSIONS CONTAINING AGENTS CAUSING APOPTOSIS | 2011 |
|
RU2598345C2 |
SOLID DISPERSIONS PRODUCED BY MELT EXTRUSION AND CONTAINING APOPTOSIS-INDUCING AGENT | 2011 |
|
RU2577859C2 |
Authors
Dates
2024-12-02—Published
2020-10-23—Filed